key: cord-0252400-j1hqa0w3 authors: Marjani, Majid; Tabarsi, Payam; Moniri, Afshin; Hashemian, Seyed Mohammadreza; Nadji, Seyed Alireza; Abtahian, Zahra; Malekmohammad, Majid; Kiani, Arda; Farzanegan, Behrooz; Eslaminejad, Alireza; Fakharian, Atefeh; Heshmatnia, Jalal; Abedini, Atefeh; Seifi, Sharareh; Yassari, Fatemeh; Mirenayat, Maryam Sadat; Rezaei, Mitra; Sheikhzade, Hakimeh; Ahmadi, Zargham Hossein; Dastan, Farzaneh; Sadeghi, Mohsen; Lookzadeh, Somayeh; Porabdollah, Mihan; Askari, Elham; Baghaei, Parvaneh; Mansourafshar, Babak; Jahangirifard, Alireza; Vasheghani, Maryam; Mokhber Dezfuli, Mojtaba; Varahram, Mohammad; Jamaati, Hamidreza; Mansouri, Davood; Zali, Alireza; Velayati, Ali Akbar title: NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals date: 2020-11-03 journal: Tanaffos DOI: nan sha: fcf56f11a822baa53bb76aa6eff8e8616e3cc0bb doc_id: 252400 cord_uid: j1hqa0w3 nan The guideline released by the National Research The severity of respiratory problems in COVID-19 is defined as follows: Mild: Symptomatic patients without pulmonary infiltration and peripheral capillary oxygen saturation (SpO2) of >93% in ambient air. of >93% in ambient air. Severe: Patients with the respiratory rate (RR) of ≥30 breath/minute, SpO2 ≤93% in ambient air, or pulmonary infiltrates in more than 50% of the lung field, not in a critical state. Critical: Patients admitted to the intensive care unit (ICU); patients who need high flow oxygen with a nasal cannula, noninvasive ventilation, or mechanical ventilation; the ones with acute respiratory distress syndrome (ARDS) or shock (5, 6) . Virologic assay by reverse transcriptase polymerase chain reaction (RT-PCR) is recommended for any patient with an indication of hospital admission. It is also necessary for symptomatic health care workers taking care of suspected or confirmed cases of COVID-19. The highest accuracy for the detection of SARS-CoV-2 can be obtained by using the lower respiratory tract specimens. However, the collection of sputum and bronchoalveolar lavage puts the healthcare workers at a higher risk due to aerosols formation. Nasopharyngeal or oropharyngeal swab/wash is the routine method to obtain a specimen for testing. It is reported that the detection of the COVID-19 virus with oropharyngeal swabs was less frequent than nasopharyngeal ones (7) . In Iran, due to restrictions on obtaining nasopharyngeal swabs, the oropharyngeal swabs or washing comprise the majority of respiratory tract specimens. Clinicians should consider that a single negative RT-PCR is not sufficient to exclude COVID-19, especially if the clinical suspicion is high. Therefore, they should consider test repetition and eventually rely on compatible symptoms, exposure history, and typical CT imaging features for the diagnosis of COVID-19 (8) . Although the most sensitive modality is the lung CTscan (10), plain chest x-ray (CXR) may be adequate in normal hosts. For immunocompromised patients, a CTscan of the lung is highly recommended. Routine use of CT-scan, as a screening measure, among asymptomatic cases should highly be deferred (11) . Indications of in-hospital management are: RR ≥30 breath/minute; SpO2 ≤93% in ambient air, any Mild cases should be managed as an outpatient, but patient education is necessary to come back in the case of deterioration. Chloroquine (in our setting, hydroxychloroquine sulfate), as monotherapy, is recommended for outpatient therapy. It can be prescribed for symptomatic high-risk groups without pneumonia; two tablets b.i.d for the first day and then one tablet b.i.d for 5-10 days (12) . In the hospital, when lopinavir/ritonavir is the basic regimen, (13) it is recommended to prescribe hydroxychloroquine just on the first day with a dosage of two tablets b.i.d in order to prevent serious interactions. In a recent observational study, the administration of hydroxychloroquine was not associated with the decrease of intubation or mortality rates (14) . Therefore, recommendations for the prescription of this drug to treat COVID-19 may change in the future. Lopinavir/ritonavir, sold as Kaletra®, is the basic regimen for the cases admitted to hospitals, recommended by the Iranian National COVID-19 Scientific Program. Its efficacy is controversial (4) , and in a recent study, no benefit was observed with lopinavir-ritonavir treatment beyond the standard care in hospitalized adult patients with severe COVID-19 (15) . It is prescribed as two 200/50 mg tablets b.i.d. Kaletra® causes critical adverse effects and interacts with other drugs. The most serious one is the QT interval prolongation and life-threatening arrhythmia (4) . Concomitant administration of drugs with the QT prolongation effects, such as fluoroquinolones, methadon, ondansetron, and metoclopramide, should be avoided in order to prevent arrhythmia. Concomitant administration of Kaletra® with rivaroxaban, lovastatin, simvastatin, colchicine, cisapride, and sildenafil to treat pulmonary artery hypertension is contraindicated (16) . It is necessary to get the baseline ECG, and if the corrected QT interval is longer than 500 msec, the drug should be discontinued. For the QT intervals between 450 and 500 msec, the daily repetition of ECG is recommended. Correction of serum electrolytes, such as potassium >4 mEq/L and magnesium >3 mEq/L, is recommended to decrease the chance of arrhythmia (16) . The most frequent problem with Kaletra® is gastrointestinal upset. Taking tablets with food may decrease the chance of this problem (17) . Kaletra® should be prescribed for minimally seven days, but this period can be extended to 14 days (4). The preliminary findings support the administration of remdesivir to treat hospitalized patients with COVID-19, especially before the disease progression leading patients to require mechanical ventilation (18) . Remdesivir is administered intravenously as a 200-mg loading dose on day 1, followed by a 100-mg maintenance dose administered daily for of 5 to 10 days (19, 20) . there is no specific recommendation in the case of hepatic impairment (4). As the recommendation of the National Scientific Committee of COVID-19, and termination of seasonal influenza circulation in the community, oseltamivir is no longer prescribed. Also, ribavirin is withdrawn from the COVID-19 drug regimen in Iran. In the case of the clinician request, one more unit can be transfused after 24 hours for unresponsive cases (34, 36, 37) . Criteria for the ICU admission of patients with COVID- There are two types of hypoxic patients with COVID-19 pneumonia and different mechanisms and pathophysiology, clearly distinguishable by the lung CTscan. In the first group, lung compliance is nearly normal, without ARDS, and in the second, the compliance is low with ARDS. In type 2 patients, in addition to viral pneumonia, they likely have self-induced lung injury due to vigorous inspiratory efforts leading to highly negative intrathoracic pressures and increased edema. Therefore, early intubation and subsequent invasive mechanical ventilation in rapidly progressing respiratory distress can diminish the change from type 1 to type 2 and decrease the risk of self-induced lung injury (39, 40) . We recommend NIV versus early intubation in selected patients with COVID-19 that can tolerate masks, are cooperative, and have no signs of severe respiratory distress. Whenever any intolerance or disadvantages of NIV are suspected, the strategy is changed to the early invasive ventilation protocol. The main concern about NIV is the aerosol formation and hazard for health care staff (41 Also, ventilation in the prone position is recommended as a rescue maneuver in type 1 and as a long-term treatment in type 2 patients (39) . An early tracheostomy with preferred the mini-surgical percutaneous dilatational tracheostomy method is recommended (42) . For the patients admitted to ICU with any stage of ARDS, the prescription of corticosteroids is recommended to decrease the inflammation. The recommended dose is 20 mg dexamethasone daily from day 1 to 5, then 10 mg daily from day 6 to 10. This approach is applied based on the study by Villar et al., (43) in the rapid progression of ARDS in patients with COVID-19 in order not to lose the time. In patients under mechanical ventilation, with Indication of stress ulcer prophylaxis is similar to those of other patients admitted to hospitals. The decision to discharge patients is clinical-based. Overall admission duration of minimally seven days is recommended. The following criteria are recommended for discharge -Tolerance of oral intake PCR testing before discharge is necessary, but the negative result PCR is not mandatory for patient discharge, although it is preferable. The patient has to be isolated in his or her house for minimally two weeks. Doctors and nurses should train any patient before discharge from the hospital both verbally and by providing pamphlets, especially in the infection control measures. If follow-up imaging is necessary, it recommends 6-8 weeks after discharge. The selection of the modality is on the basis of extension of involvement in the previous imaging studies. Currently, there is no evidence of any clinical trial supporting any prophylactic regimen (4). We do not recommend the use of any drug for the prevention of COVID-19 by health care workers or others. A Novel Coronavirus from Patients with Pneumonia in China World Health Organization The Required Confronting Approaches Efficacy and Time to Control COVID-19 Outbreak in Iran Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Clinical management of severe acute respiratory infection when COVID-19 is suspected. Interim guidance Characteristics of and Important Lessons From the Coronavirus Disease Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Detection of SARS-CoV-2 in Different Types of Clinical Specimens Clinical Characteristics of Coronavirus Disease 2019 in China Advice on the use of point-of-care immunodiagnostic tests for COVID-19. Scientific Brief Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Lopinavir and ritonavir IL: Abbvie Compassionate Use of Remdesivir for Patients with Severe Covid-19 Remdesivir for the Treatment of Covid-19 -Preliminary Report Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Solidarity" clinical trial for COVID-19 treatments Favipiravir, an anti-influenza drug against life-threatening RNA virus infections Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 Type 1 interferons as a potential treatment against COVID-19 Interferon beta-1b for COVID-19 Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multicentre, randomized, controlled trial High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE) Why tocilizumab could be an effective treatment for severe COVID-19? Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Early safety indicators of COVID-19 convalescent plasma in 5,000 patients COVID-19: Immunology and treatment options Recommendations for Investigational COVID-19 Convalescent Plasma. Accessed An EU programme of COVID-19 convalescent plasma collection and transfusion ICU Admission, Discharge, and Triage Guidelines: A Framework to Enhance Clinical Operations, Development of Institutional Policies, and Further Research COVID-19 pneumonia: ARDS or not? Ventilatorinduced lung injury Non-Invasive versus Invasive Ventilation in COVID-19: One Size Does Not Fit All A Prospective Randomized Study Comparing Minisurgical Percutaneous Dilatational Tracheostomy With Surgical and Classical Percutaneous Tracheostomy: A New Method Beyond Contraindications Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial COVID-19 and its implications for thrombosis and anticoagulation